

3. Ceresetto JM, Duboscq C, Fondevila C, Tezanos M. Hemofilia Adquirida (inhibidor adquirido del factor VIII). *Medicina* (Buenos Aires). 2015;75:231–8.
 4. Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. *Haematologica*. 2009;94:566–75.
 5. Baudo F, Collins P, Huth-Kühne A, Lévesque H, Marco P, Nemes L, et al., EACH2 registry contributors. Management of bleeding in acquired hemophilia A: Results from the European Acquired Haemophilia (EACH2) Registry. *Blood*. 2012;120:39–46.
 6. Delgado J, Jiménez-Yuste V, Hernando-Navarro F, Villar A. Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors. *Br J Haematol*. 2003;121:21–35.
 7. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al., UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: A 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. *Blood*. 2007;109:1870–7.
 8. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK, MIBS Study Group. Polymorphisms in the IL-10 but not in the IL-1b and IL-4 genes are associated with inhibitor development in patients with hemophilia A. *Blood*. 2006;107:3167–72.
 9. Kessler CM, Knöbl P. Acquired haemophilia: An overview for clinical practice. *Eur J Haematol*. 2015;95 Suppl 81:36–44.
 10. Borg JY, Guillet B, Le Cam-Duchez V, Goudemand J, Lévesque H, SACHA Study Group. Outcome of acquired haemophilia in France: The prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquisée) registry. *Haemophilia*. 2013;19:564–70.
- Katherin Clareth Castillo Vázquez^{a,*},
Raquel Ramírez-Martín^{a,b}, Eduardo García Pérez^{a,c}
y Cristina Zúñiga Bartolomé^a
- ^a Servicio de Geriatria, Hospital Universitario La Paz, Madrid, España
^b Instituto de Investigación Biomédica, Hospital Universitario La Paz (IdiPaz), Madrid, España
^c Servicio de Hematología, Hospital Universitario La Paz, Madrid, España
- * Autor para correspondencia.
Correo electrónico: katycastillo8812@gmail.com
(K.C. Castillo Vázquez).

<https://doi.org/10.1016/j.regg.2022.09.005>

0211-139X/ © 2022 SEGG. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Impact of COVID-19 pandemic in terms of incidence and lethality in nursing homes



Impacto de la pandemia de COVID-19 en términos de incidencia y letalidad en residencias de ancianos

Dear Editor,

We would like to share ideas on the publication “Impact of COVID-19 pandemic in terms of incidence and lethality in nursing homes in Galicia (Spain).¹” According to Losada-Castillo et al., monitoring COVID-19 in nursing homes is crucial for understanding the dynamics of the disease. According to Losada-analysis, Castillo's the sixth wave had the highest incidence and the lowest lethality, with the first wave having the highest lethality.¹ Due to the effects of vaccination, the incidence of the fourth and fifth waves was decreased.¹

We both concur that patterns of incidence and fatality in several COVID-19 waves may be due to chance. The impacts of vaccination may be to blame for the lower occurrence. But it's important to be aware of other complicating factors. It is important to emphasize the consequences of the SARS CoV2 variant's molecular mutation. The virulence of the virus could alter as a result of a molecular change.² Additionally, asymptomatic COVID-19, which is a prevalent condition, may have affected several patients.³ Those who had COVID-19 in the past but had no symptoms may be immune to a potential reinfection during the present wave.

Funding

None.

Conflict of interest

None.

Acknowledgement

None.

Bibliografía

1. Losada-Castillo I, Santiago-Pérez MI, Naveira-Barbeito G, Otero-Barros MT, Pérez-Martínez O, Zubizarreta-Alberdi R. Impact of COVID-19 pandemic in terms of incidence and lethality in nursing homes in Galicia (Spain). *Rev Esp Geriatr Gerontol*. 2022, <http://dx.doi.org/10.1016/j.regg.2022.08.003>. S0211-139X(22)00100-7. Online ahead of print.
2. Kannan S, Shaik Syed Ali P, Sheeza A. Evolving biothreat of variant SARS-CoV-2 – molecular properties, virulence and epidemiology. *Eur Rev Med Pharmacol Sci*. 2021;25:4405–12.
3. Joob B, Wiwanitkit V. Letter to the Editor: Coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. *J Prev Med Public Health*. 2020;53:70.

Pathum Sookaromdee^{a,*}, Viroj Wiwanitkit^b

^a Private Academic Consultant, Bangkok, Thailand

^b Adjunct Professor, Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria

* Corresponding author.

E-mail address: pathumsook@gmail.com (P. Sookaromdee).

<https://doi.org/10.1016/j.regg.2022.09.007>

0211-139X/ © 2022 SEGG. Published by Elsevier España, S.L.U. All rights reserved.